SkyOak Wealth’s Alnylam Pharmaceuticals ALNY Stock Holding History

SkyOak Wealth’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$251K	Hold	760	–	–	0.05%	205
2025 Q4	$302K	Sell	760 -87	-10%	-$38.5K	0.05%	181
2025 Q3	$386K	Buy	+847	New	+$345K	0.07%	150
2021 Q3	–	Sell	-1,681	Closed	-$285K	–	233
2021 Q2	$285K	Sell	1,681 -27	-2%	-$3.95K	0.08%	177
2021 Q1	$245K	Sell	1,708 -1,837	-52%	-$276K	0.07%	192
2020 Q4	$461K	Buy	+3,545	New	+$473K	0.14%	134

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SkyOak Wealth's ALNY Position: Q1 2026 in Review

SkyOak Wealth held its Alnylam Pharmaceuticals (ALNY) position steady in Q1 2026 at 760 shares worth $251K. The position accounts for 0.05% of the portfolio, ranked #205.

SkyOak Wealth first reported a position in ALNY in Q4 2020 and has held it in 6 quarters since. The position peaked at $461K in Q4 2020. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

SkyOak Wealth held 760 shares of Alnylam Pharmaceuticals worth $251K as of Q1 2026.
SkyOak Wealth left its Alnylam Pharmaceuticals share count unchanged in Q1 2026.
Alnylam Pharmaceuticals made up 0.05% of SkyOak Wealth's portfolio in Q1 2026, its #205 holding.
SkyOak Wealth first reported a position in Alnylam Pharmaceuticals in Q4 2020 and has held it in 6 quarters since.
SkyOak Wealth's Alnylam Pharmaceuticals position peaked at $461K in Q4 2020.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on SkyOak Wealth's 13F filing for Q1 2026, filed 30 Apr 2026.